Nonrandomized trial evaluates remote symptom monitoring impact on health care use in cancer patients, suggesting benefits in reducing hospitalizations.
Key Points
This research aims to assess the impact of remote symptom monitoring on health care utilization among cancer patients receiving systemic treatment.
Nonrandomized controlled trial conducted at 2 Alabama-based academic institutions.
Participants included 1392 patients receiving remote symptom monitoring and 4557 historical controls; data analyzed from May to October 2024.
Utilization of adjusted modified Poisson models to estimate relative risk of health care utilization.
Hospitalizations were 19% lower at 3 months (RR, 0.81; 95% CI, 0.73-0.91) and 13% lower at 6 months (RR, 0.87; 95% CI, 0.80-0.96).
ICU admissions showed no significant difference at 3 months (RR, 0.82; 95% CI, 0.59-1.13) and 6 months (RR, 0.83; 95% CI, 0.65-1.06).
ED visits were similar for both groups at 3 months (RR, 1.02; 95% CI, 0.89-1.16) and 6 months (RR, 1.03; 95% CI, 0.92-1.15).